Two clinical trials investigating the combination of these vaccinations with the checkpoint inhibitor nivolumab in advanced NSCLC are ongoing: one with TG4010 (https://clinicaltrials.gov/ NCT02823990) and one with CV301 (NCT02840994), a vaccine targeting both MUC1 and carcinoembryonic antigen. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.